A functional polymorphism in the promoter region of IL-33 is associated with the reduced risk of colorectal cancer

Biomark Med. 2019 May;13(7):567-575. doi: 10.2217/bmm-2018-0249. Epub 2019 May 29.

Abstract

Aim: We aimed to investigate IL-33 polymorphisms with risk of colorectal cancer (CRC). Materials & methods:IL-33 rs7025417 and rs1332290 were genotyped using a quantitative allelic Taqman assay. The expression of IL-33 mRNA was determined by real-time PCR and promoter activity was assayed using the Dual-Luciferase Reporter Assay. Results: The IL-33 rs7025417 CC genotype and C allele may decrease CRC risk. The IL-33 rs1332290 AC carriers had an increased risk of developing clinical Stage III-IV CRC. Lower levels of IL-33 mRNA were present in individuals with the rs7025417 CC genotype. Moreover, the rs7025417 C allele suppressed promoter activity of IL-33. Conclusion: These data suggest that the rs7025417 CC genotype may downregulate IL-33 mRNA and subsequently reduce the risk of CRC.

Keywords: IL-33; colorectal cancer; luciferase activity; polymorphism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Colorectal Neoplasms / genetics*
  • Colorectal Neoplasms / pathology
  • Female
  • Genetic Predisposition to Disease / genetics*
  • Humans
  • Interleukin-33 / genetics*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Polymorphism, Single Nucleotide*
  • Promoter Regions, Genetic / genetics*
  • RNA, Messenger / genetics

Substances

  • Interleukin-33
  • RNA, Messenger